Tags

Type your tag names separated by a space and hit enter

The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina.
Thromb Res. 2009 Nov; 124(5):560-4.TR

Abstract

The objective of this study was to investigate the time profiles of plasma matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinases (TIMP-1 and -2), and pregnancy associated plasma protein A (PAPP-A) in patients with acute myocardial infarction (AMI), compared to patients with stable angina pectoris (AP), all treated with percutaneous coronary intervention (PCI) with stent.

METHODS

Twenty patients with ST-elevation AMI and 10 patients with AP were included. Serum levels of the selected markers were measured before (only in the AP group) PCI, and 3 and 12 hours, 1,3,5,7 and 14 days after PCI in all patients.

RESULTS

The levels of MMP-9 and MMP-9/TIMP-1 ratio, being higher in the AMI group compared to the AP group at 3 hours, were significantly reduced 1 day after PCI (p<0.01 for both), sustaining during the study period. A similar pattern was observed in PAPP-A levels with significant reduction after 12 hours (p<0.01). In the AP group only smaller changes were observed, except from an increase in PAPP-A levels from before PCI to 3 hours (p<0.001), followed by significant reduction. No significant correlations were found between any of the measured biomarkers and the infarct size, either evaluated in the acute phase or after 6 weeks.

CONCLUSION

AMI patients treated with PCI had an early significant reduction in MMP-9, MMP-9/TIMP-1 ratio and PAPP-A when compared to patients with stable angina pectoris treated with PCI. This indicates that the metalloproteinases may be involved in the early phase of the plaque rupture process, with limited influence of the PCI procedure.

Authors+Show Affiliations

Center for Clinical Heart Research, Ullevaal University Hospital, University of Oslo, Norway.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19410278

Citation

Furenes, Eline B., et al. "The Profile of Circulating Metalloproteinases After PCI in Patients With Acute Myocardial Infarction or Stable Angina." Thrombosis Research, vol. 124, no. 5, 2009, pp. 560-4.
Furenes EB, Arnesen H, Solheim S, et al. The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina. Thromb Res. 2009;124(5):560-4.
Furenes, E. B., Arnesen, H., Solheim, S., Grøgaard, H. K., Hoffmann, P., & Seljeflot, I. (2009). The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina. Thrombosis Research, 124(5), 560-4. https://doi.org/10.1016/j.thromres.2009.04.001
Furenes EB, et al. The Profile of Circulating Metalloproteinases After PCI in Patients With Acute Myocardial Infarction or Stable Angina. Thromb Res. 2009;124(5):560-4. PubMed PMID: 19410278.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina. AU - Furenes,Eline B, AU - Arnesen,Harald, AU - Solheim,Svein, AU - Grøgaard,Haakon K, AU - Hoffmann,Pavel, AU - Seljeflot,Ingebjørg, Y1 - 2009/05/01/ PY - 2008/12/23/received PY - 2009/03/13/revised PY - 2009/04/05/accepted PY - 2009/5/5/entrez PY - 2009/5/5/pubmed PY - 2010/2/19/medline SP - 560 EP - 4 JF - Thrombosis research JO - Thromb Res VL - 124 IS - 5 N2 - UNLABELLED: The objective of this study was to investigate the time profiles of plasma matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinases (TIMP-1 and -2), and pregnancy associated plasma protein A (PAPP-A) in patients with acute myocardial infarction (AMI), compared to patients with stable angina pectoris (AP), all treated with percutaneous coronary intervention (PCI) with stent. METHODS: Twenty patients with ST-elevation AMI and 10 patients with AP were included. Serum levels of the selected markers were measured before (only in the AP group) PCI, and 3 and 12 hours, 1,3,5,7 and 14 days after PCI in all patients. RESULTS: The levels of MMP-9 and MMP-9/TIMP-1 ratio, being higher in the AMI group compared to the AP group at 3 hours, were significantly reduced 1 day after PCI (p<0.01 for both), sustaining during the study period. A similar pattern was observed in PAPP-A levels with significant reduction after 12 hours (p<0.01). In the AP group only smaller changes were observed, except from an increase in PAPP-A levels from before PCI to 3 hours (p<0.001), followed by significant reduction. No significant correlations were found between any of the measured biomarkers and the infarct size, either evaluated in the acute phase or after 6 weeks. CONCLUSION: AMI patients treated with PCI had an early significant reduction in MMP-9, MMP-9/TIMP-1 ratio and PAPP-A when compared to patients with stable angina pectoris treated with PCI. This indicates that the metalloproteinases may be involved in the early phase of the plaque rupture process, with limited influence of the PCI procedure. SN - 1879-2472 UR - https://www.unboundmedicine.com/medline/citation/19410278/The_profile_of_circulating_metalloproteinases_after_PCI_in_patients_with_acute_myocardial_infarction_or_stable_angina_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0049-3848(09)00169-8 DB - PRIME DP - Unbound Medicine ER -